In all cases, we found that a combined therapy with A-1331852 and S63845 (BCL-xL and MCL-1 inhibition) significantly reduced tumour cell count compared with single drug treatment or control (Fig. 5A–D, Supplementary Fig. 5B–E). This evidence concerns the gene MCL1 and neoplasm.